Skip to main content

Table 2 Basic demographic characteristics of enrolled CKD patients

From: Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways

 

No-KA

KA

p value

(n = 175)

(n = 148)

CKD stage

3

123 (0.703)

78 (0.527)

0.000

4

42 (0.240)

42 (0.284)

5

10 (0.057)

28 (0.189)

Gender

Man

108 (0.62)

78 (0.52)

0.114

Woman

67 (0.38)

70 (0.48)

Age (year)

46.7 ± 12.6

46.0 ± 11.7

0.601

Education

Primary

26 (0.15)

25 (0.17)

0.030

Secondary

96 (0.55)

97 (0.66)

Higher

53 (0.30)

26 (0.16)

Occupation

Manual worker

17 (0.10)

30 (0.20)

0.021

Brain-worker

77 (0.44)

52 (0.35)

Unemployed/retiree

81 (0.46)

66 (0.45)

Complication

No

119 (0.68)

101 (0.68)

1.000

Yes

56 (0.32)

47 (0.32)

Smoke

No

113 (0.65)

97 (0.66)

0.793

Sometimes

5 (0.03)

3 (0.02)

Yes

57 (0.33)

43 (0.29)

Alcohol

No

123 (0.70)

107 (0.72)

0.381

Yes

52 (0.30)

36 (0.24)

  1. Italic values indicate significance of p value (p < 0.05)